From epidemiological and clinical point of view, inhibitors of cyclooxygenases (COX1 and COX-2) such as nonsteroidal anti-inflammatory drugs (NSAIDs) are useful in the chemo-prevention and management of CRC [8–10]. The gene discussed is PTGS2; the disease is colorectal carcinoma.